Australian penny stock Zelda Therapeutics (ASX:ZLD) announced last week that it has completed an observation trial in Chile, and is reporting successful results for treating core symptoms of autism with medical cannabis extracts. Zelda officials say they now plan to build on those results with clinical trials in the second half of 2017.
The trial, in collaboration with a Chilean medical cannabis and alternative healthcare non-profit called Fundación Daya, aimed to treat core autism symptoms including difficulties with social interaction, language and repetitive behaviour.
The results found that in a cohort of 21 patients (median age of 9 years and 10 months), cannabis extracts were significantly more effective than the conventional medicines the children were using, including atypical antipsychotics.
Patients in the study were treated over a 12-week period and were examined by EEG, neuropsychological analysis, metabolism and genetic tests.Those treated with cannabis extracts demonstrated significant improvements in